Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays
- Conditions
- Peritoneal Mesothelioma
- Interventions
- Genetic: comparative genomic analysis
- Registration Number
- NCT02834234
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Peritoneal mesothelioma is a rare disease representing one third of all mesothelioma and nothing is known about molecular characteristics of this disease. As main cancers, genetic heterogeneity is probable. This genomic profiling associates Comparative Genomic Hybridization (CGH) array, BAP1 sequencing and gene expression in order to discover a biomarker that could be used in the treatment of this rare disease. Corresponding histopathological and immunohistochemical report as all clinical data are available. All data with be merged to underline a few genes of interest on which we will focus our next investigations. Depending of our preliminary results, BAP1 mutations are expected, as it was also described in pleural mesothelioma. Mutations in oncogenic drivers that could be targeted by specific therapy will be on particular interest in management of this rare disease with bad prognosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
- surgical biopsy od the peritoneal tumor with frozen samples
- age > 18 years old
- absence of peritoneal mesothelioma
- absence of frozen samples
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Peritoneal mesothelioma specimens comparative genomic analysis The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group. The CGH arrays will be realized on frozen samples (for the comparative genomic analysis).
- Primary Outcome Measures
Name Time Method BAP1 mutations Day 0 CGH Array
- Secondary Outcome Measures
Name Time Method